X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New poll shows Americans reject Medicare “negotiation” once they learn more about the policy

By Cynthia Hicks  |    October 15, 2021
As the debate in Washington around drug pricing proposals continues to intensify, a new Ipsos/PhRMA poll shows Medicare “negotiation” is not nearly as popular as some might suggest. Survey...   Read More

New report: To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and the health system

By Gabby Migliara  |    October 14, 2021
A new study from the Employee Benefit Research Institute (EBRI) compared the difference in price for 72 physician-administered outpatient medicines – representing 73% of medicine spending –...   Read More

What is Kaiser Family Foundation up to?

By Brian Newell  |    October 12, 2021
For years, Kaiser Family Foundation (Kaiser) has reminded lawmakers that Americans are opposed to government “negotiation” in drug pricing should it lead to less access to medicines and destroy...   Read More

Recognizing Hepatitis R&D on World Hepatitis Day

By Andrew Powaleny  |    July 28, 2021
Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. There are five main hepatitis viruses, with types A, B, C most common. In 2018, the Centers for Disease...   Read More

New reports shed light on key facts about medicines and affordability

By Brian Newell  |    June 8, 2021
A recently released report by IQVIA – an independent organization specializing in health care research – provides new data showing prices for brand medicines went down last year. The report offers...   Read More

How strengthening the biosimilar marketplace benefits patients

By Andrew Powaleny  |    May 18, 2021
Biologics are medicines that are made from living organisms through highly complex manufacturing processes and include a wide variety of medicines such as therapeutic proteins, monoclonal...   Read More

New report demonstrates development of new medicines relies on private sector expertise and investment

By John Corea  |    May 10, 2021
America’s biopharmaceutical companies are at the heart of a research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. Critical to this...   Read More

West Virginia becomes the first state to lower patient costs by sharing the savings

By Scott LaGanga  |    April 20, 2021
In a historic moment for patient affordability, last week West Virginia became the first state in the nation to adopt ground-breaking legislation, HB2263, requiring insurers and their PBMs to...   Read More

Top five issues voters want addressed in the administration’s first 100 days

By Mark Keida  |    February 18, 2021
When voters cast their ballots in the 2020 election, they made clear their focus on getting COVID-19 under control and fixing the economy. However, health care was still important to many voters,...   Read More

Insurers shift medicine costs to patients with severe chronic illnesses

By Gabby Migliara  |    February 1, 2021
For many patients with complex and chronic conditions, high out-of-pocket costs for medicines pose a significant challenge. Recent research revealed a broken insurance system that fails to help...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates